相似文献
1
Oral iron supplementation with ferric maltol in patients with pulmonary hypertension.
Eur Respir J. 2020 Nov 12;56(5). doi: 10.1183/13993003.00616-2020. Print 2020 Nov.
2
Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
Inflamm Bowel Dis. 2015 Mar;21(3):579-88. doi: 10.1097/MIB.0000000000000314.
3
Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease.
Expert Opin Pharmacother. 2015;16(18):2859-67. doi: 10.1517/14656566.2015.1096929. Epub 2015 Nov 23.
4
Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Ann Pharmacother. 2021 Feb;55(2):222-229. doi: 10.1177/1060028020941014. Epub 2020 Jul 7.
5
Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test.
J Clin Pharm Ther. 1991 Apr;16(2):117-22. doi: 10.1111/j.1365-2710.1991.tb00292.x.
6
Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat.
Br J Pharmacol. 1991 Feb;102(2):408-14. doi: 10.1111/j.1476-5381.1991.tb12187.x.
7
Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat.
Br J Pharmacol. 1991 Mar;102(3):723-9. doi: 10.1111/j.1476-5381.1991.tb12240.x.
8
Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):229-238. doi: 10.1007/s13318-016-0334-5.
9
The importance of reductive mechanisms for intestinal uptake of iron from ferric maltol and ferric nitrilotriacetic acid (NTA).
J Pharm Pharmacol. 1990 Apr;42(4):279-82. doi: 10.1111/j.2042-7158.1990.tb05408.x.
10
Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate.
J Pharm Pharmacol. 1990 Apr;42(4):276-9. doi: 10.1111/j.2042-7158.1990.tb05407.x.
引用本文的文献
1
Diagnosis and Management of Pulmonary Hypertension: New Insights.
Diagnostics (Basel). 2024 Sep 16;14(18):2052. doi: 10.3390/diagnostics14182052.
2
Intravenous iron supplementation in pulmonary hypertension groups 1 to 4.
Int J Med Sci. 2024 Aug 1;21(11):2011-2020. doi: 10.7150/ijms.92904. eCollection 2024.
3
Immature reticulocyte fraction: A novel biomarker of hemodynamic severity in pulmonary arterial hypertension.
Pulm Circ. 2024 Aug 5;14(3):e12421. doi: 10.1002/pul2.12421. eCollection 2024 Jul.
4
Iron Deficiency in Heart Failure and Pulmonary Hypertension.
Curr Treat Options Cardiovasc Med. 2022 Dec;24(12):213-229. doi: 10.1007/s11936-022-00971-4. Epub 2022 Oct 4.
5
No genetic causal association between iron status and pulmonary artery hypertension: Insights from a two-sample Mendelian randomization.
Pulm Circ. 2024 Apr 17;14(2):e12370. doi: 10.1002/pul2.12370. eCollection 2024 Apr.
6
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Int J Mol Sci. 2024 Apr 25;25(9):4654. doi: 10.3390/ijms25094654.
7
Connective tissue disease-associated pulmonary hypertension: A comprehensive review.
Pulm Circ. 2023 Dec 11;13(4):e12276. doi: 10.1002/pul2.12276. eCollection 2023 Oct.
8
Dietary intakes of total, nonheme, and heme iron and hypertension risk: a longitudinal study from the China Health and Nutrition Survey.
Eur J Nutr. 2023 Dec;62(8):3251-3262. doi: 10.1007/s00394-023-03230-9. Epub 2023 Aug 9.
9
Is iron deficiency caused by mutations or dysfunction in pulmonary arterial hypertension patients?
Pulm Circ. 2023 Jun 7;13(2):e12242. doi: 10.1002/pul2.12242. eCollection 2023 Apr.
10
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.
Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970.
本文引用的文献
1
Iron Deficiency in Heart Failure: An Overview.
JACC Heart Fail. 2019 Jan;7(1):36-46. doi: 10.1016/j.jchf.2018.07.015. Epub 2018 Dec 12.
2
Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer ) versus ferric carboxy-maltose (Ferinject ). A single center, cohort study.
Br J Clin Pharmacol. 2019 Feb;85(2):385-392. doi: 10.1111/bcp.13805. Epub 2018 Dec 11.
3
Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency.
Pulm Circ. 2015 Sep;5(3):466-72. doi: 10.1086/682217.
4
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
5
Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
Inflamm Bowel Dis. 2015 Mar;21(3):579-88. doi: 10.1097/MIB.0000000000000314.
6
Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Int J Cardiol. 2014 Aug 1;175(2):233-9. doi: 10.1016/j.ijcard.2014.04.233. Epub 2014 Apr 27.
7
Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension.
Rheumatology (Oxford). 2014 Feb;53(2):285-92. doi: 10.1093/rheumatology/ket331. Epub 2013 Oct 22.
8
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights.
J Am Coll Cardiol. 2011 Jul 12;58(3):300-9. doi: 10.1016/j.jacc.2011.02.057.
9
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target.
Eur Respir J. 2011 Dec;38(6):1453-60. doi: 10.1183/09031936.00037711. Epub 2011 Apr 8.
10
Iron deficiency is common in idiopathic pulmonary arterial hypertension.
Eur Respir J. 2011 Jun;37(6):1386-91. doi: 10.1183/09031936.00100510. Epub 2010 Sep 30.
Zotero 插件